Pharmacological Reports, Journal Year: 2023, Volume and Issue: 75(6), P. 1410 - 1444
Published: Oct. 31, 2023
Language: Английский
Turkish Journal of Biochemistry, Journal Year: 2025, Volume and Issue: unknown
Published: March 5, 2025
Abstract Objectives Diabetic cardiomyopathy (DCM) is a chronic complication of type 2-diabetes mellitus, leading to heart failure. Addressing DCM requires comprehensive therapeutic approach. This study examines the protective role Δ(9)-tetrahydrocannabinol (THC) in by assessing its impact on cardiac function, inflammation, oxidative stress, and mitochondrial health exploring involvement SIRT3/FOXO1 TLR4/NF-κB/NLRP3 signaling pathways. Methods Over four-week period, THC (1.5 mg/kg, administered intraperitoneally) was given type-2 diabetic Sprague-Dawley rats. Cardiac function evaluated using carotid catheter vivo while integrity assessed through fluorometric techniques. Moreover, biochemical biomarkers protein expression key proteins were measured via ELISA immunoblotting. Results Compared untreated rats, treatment showed pronounced effects, improving reducing markers DCM. It significantly lowered NF-κB, NLRP3, IL-1β, TNF-α diabetes-induced stress heart, as evidenced decreased malondialdehyde levels increased glutathione catalase levels. also prevented membrane depolarization reactive oxygen species production substantially suppressed upregulation TLR4 MyD88 increasing FOXO1 Inhibition pathway 3-TYP reversed cardioprotective effects THC, negating NF-κB/NLRP3/IL-1β without influencing TLR4/MyD88. Conclusions These results underscore that offers significant protection against damage mitigating functional changes associated with DCM, primarily modulation SIRT3/FOXO1/mitochondrial
Language: Английский
Citations
0
Exploration of Neuroprotective Therapy, Journal Year: 2025, Volume and Issue: 5
Published: March 9, 2025
Neurodegenerative diseases are a complex ensemble of ailments characterized by progressive neuronal deterioration and ultimate loss, resulting in drastic impairments memory, cognition other brain functions. These incapacitating conditions challenging for the public health system worldwide, with unfortunately no real cure lack efficient drugs capable delaying or reversing these diseases. In this context, endocannabinoid exogenous cannabinoids represent an interesting field research due to numerous studies highlighting neuroprotective effect from different sources, i.e., endogenous, phytocannabinoids, synthetic cannabinoids. This review highlights multilayered effects block progression neurodegeneration minimize deleterious insults that affect brain. We illustrate examples showing main modulate components response at level three major mechanisms involved neurodegeneration: neuroinflammation, excitotoxicity, oxidative stress.
Language: Английский
Citations
0
Exploration of Neuroprotective Therapy, Journal Year: 2025, Volume and Issue: 5
Published: March 9, 2025
Neurodegenerative diseases are a complex ensemble of ailments characterized by progressive neuronal deterioration and ultimate loss, resulting in drastic impairments memory, cognition other brain functions. These incapacitating conditions challenging for the public health system worldwide, with unfortunately no real cure lack efficient drugs capable delaying or reversing these diseases. In this context, endocannabinoid exogenous cannabinoids represent an interesting field research due to numerous studies highlighting neuroprotective effect from different sources, i.e., endogenous, phytocannabinoids, synthetic cannabinoids. This review highlights multilayered effects block progression neurodegeneration minimize deleterious insults that affect brain. We illustrate examples showing main modulate components response at level three major mechanisms involved neurodegeneration: neuroinflammation, excitotoxicity, oxidative stress.
Language: Английский
Citations
0
Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown
Published: April 6, 2025
Language: Английский
Citations
0
Journal of Pharmacological Sciences, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Language: Английский
Citations
0
European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177705 - 177705
Published: May 1, 2025
Language: Английский
Citations
0
Translational Stroke Research, Journal Year: 2025, Volume and Issue: unknown
Published: May 8, 2025
Language: Английский
Citations
0
Biomedicines, Journal Year: 2025, Volume and Issue: 13(6), P. 1271 - 1271
Published: May 22, 2025
Palmitoylethanolamide (PEA) is an endogenous lipid mediator belonging to the N-acyl-ethanolamine family, widely recognized for its multifaceted effects on neuroprotection, chronic pain management, and immune modulation. As a naturally occurring compound, PEA plays crucial role in maintaining homeostasis under conditions of cellular stress inflammation. Its pharmacological are primarily mediated through peroxisome proliferator-activated receptor-alpha (PPAR-α) activation, alongside indirect modulation cannabinoid receptors CB1 CB2, as well interactions with novel targets such GPR55 TRPV1. These molecular mechanisms underpin broad therapeutic potential, particularly management neuroinflammatory neurodegenerative disorders, syndromes, dysregulation. A major advancement research has been development ultramicronized palmitoylethanolamide (umPEA), which significantly enhances bioavailability efficacy by facilitating better tissue absorption interaction key pathways. Preclinical clinical studies have demonstrated that umPEA effective reducing neuroinflammation, stabilizing mast cells, enhancing endocannabinoid system activity, making it promising candidate integrative approaches neuropsychiatric inflammatory diseases. Given well-established safety profile, represents attractive alternative or adjunct conventional anti-inflammatory analgesic therapies. This communication provides comprehensive overview action applications both umPEA, emphasizing their emerging practice personalized medicine.
Language: Английский
Citations
0
Brain Sciences, Journal Year: 2022, Volume and Issue: 12(12), P. 1596 - 1596
Published: Nov. 22, 2022
The use of cannabinoids as therapeutic drugs has increased among aging populations recently. Age-related changes in the endogenous cannabinoid system could influence effects therapies that target system. At preclinical level, cannabidiol (CBD) induces anti-amyloidogenic, antioxidative, anti-apoptotic, anti-inflammatory, and neuroprotective effects. These findings suggest a potential role to neurodegenerative disorders such Parkinson’s disease (PD) Alzheimer. Emerging evidence suggests CBD tetrahydrocannabinol have therapeutic-like on dementias. In clinical practice, are being used off-label relieve symptoms PD AD. fact, patients using cannabis compounds for treatment tremor, non-motor symptoms, anxiety, sleep assistance PD, managing responsive behaviors dementia agitation. However, strong from trials is scarce most indications. Some clinicians consider an alternative older adults bearing Alzheimer’s with poor response first-line treatments. our concept experience, should never be considered but regarded adjuvant therapy specific situations commonly seen practice. To mitigate risk adverse events, traditional dogma geriatric medicine, starting low dose proceeding slow titration regime, also employed cannabinoids. this review, we aimed address AD discuss practice these disorders.
Language: Английский
Citations
15
Neuroscience & Biobehavioral Reviews, Journal Year: 2023, Volume and Issue: 155, P. 105439 - 105439
Published: Oct. 27, 2023
Language: Английский
Citations
9